Artelo biosciences announces reverse stock split

Solana beach, calif., june 11, 2025 (globe newswire) -- artelo biosciences, inc. (nasdaq: artl), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced that on may 20, 2025 artelo's board of directors approved a 6-for-1 reverse stock split (“reverse split”) of the company's common stock (“common stock”).
ARTL Ratings Summary
ARTL Quant Ranking